GNE-6776
目录号 : GC32727
GNE-6776 is a potent, non-covalent, selective and orally bioavailable inhibitor of USP7 with IC50 of 1.34 μM and 0.61 μM for full length USP7 and USP7 catalytic domain, respectively.
Cas No.:2009273-71-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
GNE-6776 is a potent, non-covalent, selective and orally bioavailable inhibitor of USP7 with IC50 of 1.34 μM and 0.61 μM for full length USP7 and USP7 catalytic domain, respectively.
[1] Lorna Kategaya, et al. Nature. 2017 Oct 26;550(7677):534-538.
Cell experiment: | EOL-1 cells are seeded into 384-well plates 24 h before compound addition. Cells are then incubated with compound (e.g., GNE-6776; 0.003, 0.009, 0.027, 0.082, 0.25, 0.74, 2.22, 6.67, and 20 μM) for 72 h or 120 h before assaying viability. Assays are performed in biological triplicate. Cells are incubated (37°C, 5% CO2) in RPMI-1640, 2.5% FBS (72 h assay) or 5% FBS (120 h assay), and 2 mM glutamine throughout the assay. The reported IC50 and mean viability metrics are as follows: IC50 is the dose at which the estimated inhibition is 50% relative to untreated wells (that is, absolute IC50). The mean viability is calculated[1]. |
Animal experiment: | Mice[1]GNE-6776 is administered at 200 mg/kg (body weight) by oral gavage to female C.B-17 SCID mice, aged 12-16 weeks (n=3 per time point). No randomization is used for DMPK studies. At 0.5, 1, 2, 4, 8 and 24 h post-dose, blood samples are collected by terminal cardiac puncture into anticoagulant tubes (EDTA). Clarified plasma is then transferred to a fresh tube and snap frozen. GNE-6776 plasma concentrations are determined by LC-MS/MS[1]. |
References: [1]. Kategaya L, et al. USP7 small-molecule inhibitors interfere with ubiquitin binding. Nature. 2017 Oct 26;550(7677):534-538. | |
| Cas No. | 2009273-71-4 | SDF | |
| Canonical SMILES | CCC(C(C1=CC=C(O)C=C1)=C(N)N=C2)=C2C3=CC=C(C(NC)=O)N=C3 | ||
| 分子式 | C20H20N4O2 | 分子量 | 348.4 |
| 溶解度 | DMSO : ≥ 310 mg/mL (889.78 mM) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.8703 mL | 14.3513 mL | 28.7026 mL |
| 5 mM | 0.5741 mL | 2.8703 mL | 5.7405 mL |
| 10 mM | 0.287 mL | 1.4351 mL | 2.8703 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet